MedTrace Logo

24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination

NCT00331240 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2014-05-12

No results posted yet for this study

Summary

The purpose of this study is to compare the short-term (8 week) mean 24-hour intraocular pressure control and safety of TravTim fixed combination given once in the evening with placebo once in the morning versus TravTim given once in the morning with placebo once in the evening in patients with open-angle glaucoma.

Conditions

  • Primary Open Angle Glaucoma
  • Exfoliation Syndrome

Interventions

DRUG

travoprost/timolol fixed combination

DRUG

placebo (artificial tears)

Sponsors & Collaborators

  • Aristotle University Of Thessaloniki

    lead OTHER

Principal Investigators

  • AGP Konstas, MD, PhD · Glaucoma Unit, A University Dept of Ophthalmology, AHEPA Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
29 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2007-01-31
Completion
2007-02-28

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00331240 on ClinicalTrials.gov